Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 137

1.

Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia.

Pollyea DA, Tallman MS, de Botton S, Kantarjian HM, Collins R, Stein AS, Frattini MG, Xu Q, Tosolini A, See WL, MacBeth KJ, Agresta SV, Attar EC, DiNardo CD, Stein EM.

Leukemia. 2019 Apr 9. doi: 10.1038/s41375-019-0472-2. [Epub ahead of print]

PMID:
30967620
2.

Kinase-dead ATR differs from ATR loss by limiting the dynamic exchange of ATR and RPA.

Menolfi D, Jiang W, Lee BJ, Moiseeva T, Shao Z, Estes V, Frattini MG, Bakkenist CJ, Zha S.

Nat Commun. 2018 Dec 17;9(1):5351. doi: 10.1038/s41467-018-07798-3.

3.

Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification.

Bulik-Sullivan B, Busby J, Palmer CD, Davis MJ, Murphy T, Clark A, Busby M, Duke F, Yang A, Young L, Ojo NC, Caldwell K, Abhyankar J, Boucher T, Hart MG, Makarov V, Montpreville VT, Mercier O, Chan TA, Scagliotti G, Bironzo P, Novello S, Karachaliou N, Rosell R, Anderson I, Gabrail N, Hrom J, Limvarapuss C, Choquette K, Spira A, Rousseau R, Voong C, Rizvi NA, Fadel E, Frattini M, Jooss K, Skoberne M, Francis J, Yelensky R.

Nat Biotechnol. 2018 Dec 17. doi: 10.1038/nbt.4313. [Epub ahead of print]

PMID:
30556813
4.

[How do general practitioners promote a more equitable access for patient education?].

Fournier C, Frattini MO, Naiditch M, Traynard PY, Gagnayre R, Lombrail P.

Sante Publique. 2018 May-Jun;30(1 Suppl):69-80. doi: 10.3917/spub.184.0069. French.

PMID:
30547488
5.

Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition.

Harding JJ, Lowery MA, Shih AH, Schvartzman JM, Hou S, Famulare C, Patel M, Roshal M, Do RK, Zehir A, You D, Selcuklu SD, Viale A, Tallman MS, Hyman DM, Reznik E, Finley LWS, Papaemmanuil E, Tosolini A, Frattini MG, MacBeth KJ, Liu G, Fan B, Choe S, Wu B, Janjigian YY, Mellinghoff IK, Diaz LA, Levine RL, Abou-Alfa GK, Stein EM, Intlekofer AM.

Cancer Discov. 2018 Dec;8(12):1540-1547. doi: 10.1158/2159-8290.CD-18-0877. Epub 2018 Oct 24.

PMID:
30355724
6.

Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia.

Leeksma AC, Taylor J, Wu B, Gardner JR, He J, Nahas M, Gonen M, Alemayehu WG, Te Raa D, Walther T, Hüllein J, Dietrich S, Claus R, de Boer F, de Heer K, Dubois J, Dampmann M, Dürig J, van Oers MHJ, Geisler CH, Eldering E, Levine RL, Miller V, Mughal T, Lamanna N, Frattini MG, Heaney ML, Zelenetz A, Zenz T, Abdel-Wahab O, Kater AP.

Leukemia. 2019 Feb;33(2):390-402. doi: 10.1038/s41375-018-0215-9. Epub 2018 Jul 23.

PMID:
30038380
7.

Mixed Adenoma Well-differentiated Neuroendocrine Tumor (MANET) of the Digestive System: An Indolent Subtype of Mixed Neuroendocrine-NonNeuroendocrine Neoplasm (MiNEN).

La Rosa S, Uccella S, Molinari F, Savio A, Mete O, Vanoli A, Maragliano R, Frattini M, Mazzucchelli L, Sessa F, Bongiovanni M.

Am J Surg Pathol. 2018 Nov;42(11):1503-1512. doi: 10.1097/PAS.0000000000001123.

PMID:
30001239
8.

Gene signatures and expression of miRNAs associated with efficacy of panitumumab in a head and neck cancer phase II trial.

Siano M, Espeli V, Mach N, Bossi P, Licitra L, Ghielmini M, Frattini M, Canevari S, De Cecco L.

Oral Oncol. 2018 Jul;82:144-151. doi: 10.1016/j.oraloncology.2018.05.013. Epub 2018 May 28.

PMID:
29909889
9.

Micafungin versus posaconazole prophylaxis in acute leukemia or myelodysplastic syndrome: A randomized study.

Epstein DJ, Seo SK, Huang YT, Park JH, Klimek VM, Berman E, Tallman MS, Frattini MG, Papanicolaou GA.

J Infect. 2018 Sep;77(3):227-234. doi: 10.1016/j.jinf.2018.03.015. Epub 2018 May 7.

PMID:
29746955
10.

A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure.

Zeidan AM, Knaus HA, Robinson TM, Towlerton AMH, Warren EH, Zeidner JF, Blackford AL, Duffield AS, Rizzieri D, Frattini MG, Levy YM, Schroeder MA, Ferguson A, Sheldon KE, DeZern AE, Gojo I, Gore SD, Streicher H, Luznik L, Smith BD.

Clin Cancer Res. 2018 Aug 1;24(15):3519-3527. doi: 10.1158/1078-0432.CCR-17-3763. Epub 2018 May 1.

PMID:
29716921
11.

Highly Sensitive Virome Capture Sequencing Technique VirCapSeq-VERT Identifies Partial Noncoding Sequences but no Active Viral Infection in Cutaneous T-Cell Lymphoma.

Anderson ME, Nagy-Szakal D, Jain K, Patrone CC, Frattini MG, Lipkin WI, Geskin LJ.

J Invest Dermatol. 2018 Jul;138(7):1671-1673. doi: 10.1016/j.jid.2018.01.024. Epub 2018 Feb 7. No abstract available.

PMID:
29427587
12.

Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia.

Maslak PG, Dao T, Bernal Y, Chanel SM, Zhang R, Frattini M, Rosenblat T, Jurcic JG, Brentjens RJ, Arcila ME, Rampal R, Park JH, Douer D, Katz L, Sarlis N, Tallman MS, Scheinberg DA.

Blood Adv. 2018 Feb 13;2(3):224-234. doi: 10.1182/bloodadvances.2017014175.

13.

Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR.

Peraldo-Neia C, Cavalloni G, Fenocchio E, Cagnazzo C, Gammaitoni L, Cereda S, Nasti G, Satolli MA, Aprile G, Reni M, Avallone A, Spadi R, Venesio T, Martin V, Doglioni C, Frattini M, Aglietta M, Leone F.

PLoS One. 2018 Jan 19;13(1):e0191593. doi: 10.1371/journal.pone.0191593. eCollection 2018.

14.

Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.

DiNardo CD, Pratz KW, Letai A, Jonas BA, Wei AH, Thirman M, Arellano M, Frattini MG, Kantarjian H, Popovic R, Chyla B, Xu T, Dunbar M, Agarwal SK, Humerickhouse R, Mabry M, Potluri J, Konopleva M, Pollyea DA.

Lancet Oncol. 2018 Feb;19(2):216-228. doi: 10.1016/S1470-2045(18)30010-X. Epub 2018 Jan 12.

PMID:
29339097
15.

Deregulation of sialidases in human normal and tumor tissues.

Forcella M, Mozzi A, Stefanini FM, Riva A, Epistolio S, Molinari F, Merlo E, Monti E, Fusi P, Frattini M.

Cancer Biomark. 2018 Feb 14;21(3):591-601. doi: 10.3233/CBM-170548.

PMID:
29278877
16.

The role of Piccolo in cancer treatment: relationship with EGFR and related therapies, and a marker for new targeted therapies.

Frattini M, Molinari F, Epistolio S.

J Thorac Dis. 2017 Nov;9(11):4240-4243. doi: 10.21037/jtd.2017.10.38. No abstract available.

17.

Non-small cell lung cancer (NSCLC), EGFR downstream pathway activation and TKI targeted therapies sensitivity: Effect of the plasma membrane-associated NEU3.

Forcella M, Oldani M, Epistolio S, Freguia S, Monti E, Fusi P, Frattini M.

PLoS One. 2017 Oct 31;12(10):e0187289. doi: 10.1371/journal.pone.0187289. eCollection 2017.

18.

SensiScreen®KRAS exon 2-sensitive simplex and multiplex real-time PCR-based assays for detection of KRAS exon 2 mutations.

Riva A, BØrgesen M, Guldmann-Christensen M, Hauge Kyneb M, Voogd K, Andersen C, Epistolio S, Merlo E, Yding Wolff T, Hamilton-Dutoit S, Lorenzen J, Christensen UB, Frattini M.

PLoS One. 2017 Jun 21;12(6):e0178027. doi: 10.1371/journal.pone.0178027. eCollection 2017.

19.

Multicenter Phase II Study of Panitumumab in Platinum Pretreated, Advanced Head and Neck Squamous Cell Cancer.

Siano M, Molinari F, Martin V, Mach N, Früh M, Freguia S, Corradino I, Ghielmini M, Frattini M, Espeli V.

Oncologist. 2017 Jul;22(7):782-e70. doi: 10.1634/theoncologist.2017-0069. Epub 2017 Jun 7.

20.

KRAS mutation testing on all non-malignant diagnosis of pancreatic endoscopic ultrasound-guided fine-needle aspiration biopsies improves diagnostic accuracy.

Trisolini E, Armellini E, Paganotti A, Veggiani C, Bozzola C, Frattini M, Pizio C, Mancuso G, Andorno S, Boldorini R.

Pathology. 2017 Jun;49(4):379-386. doi: 10.1016/j.pathol.2016.12.348. Epub 2017 Apr 24.

PMID:
28450086
21.

Tubular Cytoplasmic Expression of Zinc Finger Protein SNAI1 in Renal Transplant Biopsies: A Sign of Diseased Epithelial Phenotype?

Prunotto M, Chaykovska L, Bongiovanni M, Frattini M, Cagarelli T, Weibel F, Bruschi M, de Herreros AG, Moll S.

Am J Pathol. 2017 Jan;187(1):55-69. doi: 10.1016/j.ajpath.2016.09.017. Epub 2016 Nov 15.

PMID:
27863213
22.

Cadmium-transformed cells in the in vitro cell transformation assay reveal different proliferative behaviours and activated pathways.

Forcella M, Callegaro G, Melchioretto P, Gribaldo L, Frattini M, Stefanini FM, Fusi P, Urani C.

Toxicol In Vitro. 2016 Oct;36:71-80. doi: 10.1016/j.tiv.2016.07.006. Epub 2016 Jul 16.

PMID:
27432484
23.

Hürthle Cells Adenoma of the Thyroid with Post-surgical Implants in the Neck: Clinical, Morphological, and Molecular Analysis of Three Cases.

Bongiovanni M, Uccella S, Giovanella L, Molinari F, Frattini M, Dionigi G, Piantanida E, Nobile A, Sessa F, La Rosa S.

Endocr Pathol. 2016 Dec;27(4):338-345.

PMID:
27108352
24.

TP53 alterations in pancreatic acinar cell carcinoma: new insights into the molecular pathology of this rare cancer.

La Rosa S, Bernasconi B, Frattini M, Tibiletti MG, Molinari F, Furlan D, Sahnane N, Vanoli A, Albarello L, Zhang L, Notohara K, Casnedi S, Chenard MP, Adsay V, Asioli S, Capella C, Sessa F.

Virchows Arch. 2016 Mar;468(3):289-96. doi: 10.1007/s00428-015-1882-9. Epub 2015 Nov 19.

PMID:
26586531
25.

Coordination d’appui au médecin traitant pour faciliter les parcours de ses patients.

Frattini MO, Naiditch M.

Sante Publique. 2015 Mar-Apr;1 Suppl:87-94. French. No abstract available.

PMID:
26414261
26.

EGFR and KRAS Mutations in ALK-Positive Lung Adenocarcinomas: Biological and Clinical Effect.

Sahnane N, Frattini M, Bernasconi B, Zappa F, Schiavone G, Wannesson L, Antonelli P, Balzarini P, Sessa F, Mazzucchelli L, Tibiletti MG, Martin V.

Clin Lung Cancer. 2016 Jan;17(1):56-61. doi: 10.1016/j.cllc.2015.08.001. Epub 2015 Aug 18.

PMID:
26381283
27.

[Coordination of support to general practitioners to facilitate the patient's care pathway].

Frattini MO, Naiditch M.

Sante Publique. 2015 Jan-Feb;27(1 Suppl):S87-94. French.

PMID:
26168621
28.

Molecular profiling of lung adenosquamous carcinoma: hybrid or genuine type?

Vassella E, Langsch S, Dettmer MS, Schlup C, Neuenschwander M, Frattini M, Gugger M, Schäfer SC.

Oncotarget. 2015 Sep 15;6(27):23905-16.

29.

NEU3 activity enhances EGFR activation without affecting EGFR expression and acts on its sialylation levels.

Mozzi A, Forcella M, Riva A, Difrancesco C, Molinari F, Martin V, Papini N, Bernasconi B, Nonnis S, Tedeschi G, Mazzucchelli L, Monti E, Fusi P, Frattini M.

Glycobiology. 2015 Aug;25(8):855-68. doi: 10.1093/glycob/cwv026. Epub 2015 Apr 28.

PMID:
25922362
30.

ALK testing in lung adenocarcinoma: technical aspects to improve FISH evaluation in daily practice.

Martin V, Bernasconi B, Merlo E, Balzarini P, Vermi W, Riva A, Chiaravalli AM, Frattini M, Sahnane N, Facchetti F, Mazzucchelli L, Sessa F, Tibiletti MG.

J Thorac Oncol. 2015 Apr;10(4):595-602. doi: 10.1097/JTO.0000000000000444.

31.

Laser capture microdissection is a valuable tool in the preoperative molecular screening of follicular lesions of the thyroid: an institutional experience.

Bongiovanni M, Molinari F, Eszlinger M, Paschke R, Barizzi J, Merlo E, Giovanella L, Fasolini F, Cattaneo F, Ramelli F, Mazzucchelli L, Frattini M.

Cytopathology. 2015 Oct;26(5):288-96. doi: 10.1111/cyt.12226. Epub 2014 Dec 8.

PMID:
25487739
32.

Geminin inhibits a late step in the formation of human pre-replicative complexes.

Wu M, Lu W, Santos RE, Frattini MG, Kelly TJ.

J Biol Chem. 2014 Oct 31;289(44):30810-21. doi: 10.1074/jbc.M114.552935. Epub 2014 Sep 17.

33.

Screening for the FIG-ROS1 fusion in biliary tract carcinomas by nested PCR.

Peraldo Neia C, Cavalloni G, Balsamo A, Venesio T, Napoli F, Sassi F, Martin V, Frattini M, Aglietta M, Leone F.

Genes Chromosomes Cancer. 2014 Dec;53(12):1033-40. doi: 10.1002/gcc.22212. Epub 2014 Sep 18.

PMID:
25231053
34.

BRAF mutation analysis is a valid tool to implement in Lynch syndrome diagnosis in patients classified according to the Bethesda guidelines.

Molinari F, Signoroni S, Lampis A, Bertan C, Perrone F, Sala P, Mondini P, Crippa S, Bertario L, Frattini M.

Tumori. 2014 May-Jun;100(3):315-20. doi: 10.1700/1578.17214.

PMID:
25076244
35.

HER2 in solid tumors: more than 10 years under the microscope; where are we now?

Martin V, Cappuzzo F, Mazzucchelli L, Frattini M.

Future Oncol. 2014 Jun;10(8):1469-86. doi: 10.2217/fon.14.19. Review.

PMID:
25052756
36.

FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study.

Geva R, Vecchione L, Kalogeras KT, Jensen BV, Lenz HJ, Yoshino T, Paez D, Montagut C, Souglakos J, Cappuzzo F, Cervantes A, Frattini M, Fountzilas G, Johansen JS, Høgdall EV, Zhang W, Yang D, Yamazaki K, Nishina T, Papamichael D, Vincenzi B, Macarulla T, Loupakis F, De Schutter J, Spindler KL, Pfeiffer P, Ciardiello F, Piessevaux H, Tejpar S.

Gut. 2015 Jun;64(6):921-8. doi: 10.1136/gutjnl-2014-307234. Epub 2014 Jul 10.

PMID:
25011934
37.

Influence of glenosphere design and material on clinical outcomes of reverse total shoulder arthroplasty.

Bloch HR, Budassi P, Bischof A, Agneskirchner J, Domenghini C, Frattini M, Borroni M, Zoni S, Castagna A.

Shoulder Elbow. 2014 Jul;6(3):156-64. doi: 10.1177/1758573214535574. Epub 2014 Jun 17. Erratum in: Shoulder Elbow. 2014 Oct;6(4):300.

38.

Circulating free DNA in a screening program for early colorectal cancer detection.

Perrone F, Lampis A, Bertan C, Verderio P, Ciniselli CM, Pizzamiglio S, Frattini M, Nucifora M, Molinari F, Gallino G, Gariboldi M, Meroni E, Leo E, Pierotti MA, Pilotti S.

Tumori. 2014 Mar-Apr;100(2):115-21. doi: 10.1700/1491.16389.

PMID:
24852853
39.

Well-differentiated follicular patterned tumors of the thyroid with high-grade features can metastasize in the absence of capsular or vascular invasion: report of a case.

Bongiovanni M, Mazzucchelli L, Giovanella L, Frattini M, Pusztaszeri M.

Int J Surg Pathol. 2014 Dec;22(8):749-56. doi: 10.1177/1066896914531814. Epub 2014 Apr 29.

PMID:
24788527
40.

APC alterations are frequently involved in the pathogenesis of acinar cell carcinoma of the pancreas, mainly through gene loss and promoter hypermethylation.

Furlan D, Sahnane N, Bernasconi B, Frattini M, Tibiletti MG, Molinari F, Marando A, Zhang L, Vanoli A, Casnedi S, Adsay V, Notohara K, Albarello L, Asioli S, Sessa F, Capella C, La Rosa S.

Virchows Arch. 2014 May;464(5):553-64. doi: 10.1007/s00428-014-1562-1. Epub 2014 Mar 4.

PMID:
24590585
41.

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.

Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, Chung SS, Stefanski J, Borquez-Ojeda O, Olszewska M, Qu J, Wasielewska T, He Q, Fink M, Shinglot H, Youssif M, Satter M, Wang Y, Hosey J, Quintanilla H, Halton E, Bernal Y, Bouhassira DC, Arcila ME, Gonen M, Roboz GJ, Maslak P, Douer D, Frattini MG, Giralt S, Sadelain M, Brentjens R.

Sci Transl Med. 2014 Feb 19;6(224):224ra25. doi: 10.1126/scitranslmed.3008226.

42.

Functions and Regulation of the PTEN Gene in Colorectal Cancer.

Molinari F, Frattini M.

Front Oncol. 2014 Jan 16;3:326. doi: 10.3389/fonc.2013.00326. eCollection 2013. Review.

43.

[Benchmarks for interdisciplinary health and social sciences research: contributions of a research seminar].

Kivits J, Fournier C, Mino JC, Frattini MO, Winance M, Lefève C, Robelet M.

Sante Publique. 2013 Sep-Oct;25(5):579-86. French.

PMID:
24418420
44.

Acute myeloid leukemia presenting with panhypopituitarism or diabetes insipidus: a case series with molecular genetic analysis and review of the literature.

Cull EH, Watts JM, Tallman MS, Kopp P, Frattini M, Rapaport F, Rampal R, Levine R, Altman JK.

Leuk Lymphoma. 2014 Sep;55(9):2125-9. doi: 10.3109/10428194.2013.869327. Epub 2014 Feb 24. Review.

PMID:
24286261
45.

EGFR, KRAS, BRAF, and PIK3CA characterization in squamous cell anal cancer.

Martin V, Zanellato E, Franzetti-Pellanda A, Molinari F, Movilia A, Paganotti A, Deantonio L, De Dosso S, Assi A, Crippa S, Boldorini R, Mazzucchelli L, Saletti P, Frattini M.

Histol Histopathol. 2014 Apr;29(4):513-21. doi: 10.14670/HH-29.10.513. Epub 2013 Oct 14.

PMID:
24122611
46.

CDX2 expression in columnar variant of papillary thyroid carcinoma.

Bongiovanni M, Piana S, Frattini M, Giovanella L, Spitale A, Ragazzi M, Ciarrocchi A.

Thyroid. 2013 Nov;23(11):1498-9. doi: 10.1089/thy.2013.0146. Epub 2013 Sep 19. No abstract available.

PMID:
23734674
47.

ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy.

De Dosso S, Zanellato E, Nucifora M, Boldorini R, Sonzogni A, Biffi R, Fazio N, Bucci E, Beretta O, Crippa S, Saletti P, Frattini M.

Cancer Chemother Pharmacol. 2013 Jul;72(1):159-65. doi: 10.1007/s00280-013-2181-2. Epub 2013 May 5.

PMID:
23645290
48.

Mutation analysis of the EGFR gene and downstream signalling pathway in histologic samples of malignant pleural mesothelioma.

Mezzapelle R, Miglio U, Rena O, Paganotti A, Allegrini S, Antona J, Molinari F, Frattini M, Monga G, Alabiso O, Boldorini R.

Br J Cancer. 2013 Apr 30;108(8):1743-9. doi: 10.1038/bjc.2013.130. Epub 2013 Apr 4.

49.

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia.

Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, Bartido S, Stefanski J, Taylor C, Olszewska M, Borquez-Ojeda O, Qu J, Wasielewska T, He Q, Bernal Y, Rijo IV, Hedvat C, Kobos R, Curran K, Steinherz P, Jurcic J, Rosenblat T, Maslak P, Frattini M, Sadelain M.

Sci Transl Med. 2013 Mar 20;5(177):177ra38. doi: 10.1126/scitranslmed.3005930.

50.

HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients.

Martin V, Landi L, Molinari F, Fountzilas G, Geva R, Riva A, Saletti P, De Dosso S, Spitale A, Tejpar S, Kalogeras KT, Mazzucchelli L, Frattini M, Cappuzzo F.

Br J Cancer. 2013 Feb 19;108(3):668-75. doi: 10.1038/bjc.2013.4. Epub 2013 Jan 24.

Supplemental Content

Loading ...
Support Center